# Edurant Ped (rilpivirine hydrochloride) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/rilpivirine

> The FDA approved Edurant Ped (rilpivirine hydrochloride), sponsored by JOHNSON & JOHNSON (JNJ), on March 15, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Edurant Ped (rilpivirine hydrochloride) |
| Codes |  |
| Sponsor | JOHNSON & JOHNSON (JNJ) https://sec-api.dev/companies/jnj/catalysts |
| Indications | [Human Immunodeficiency Virus Type 1](https://sec-api.dev/indications/human-immunodeficiency-virus-type-1) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### January 21, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA202022 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20210121, review_priority PRIORITY; sponsor_name JANSSEN PRODS; product EDURANT (RILPIVIRINE HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202022%22

### January 31, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA202022 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20220131, review_priority STANDARD; sponsor_name JANSSEN PRODS; product EDURANT (RILPIVIRINE HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202022%22

### March 29, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA202022 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20220329, review_priority PRIORITY; sponsor_name JANSSEN PRODS; product EDURANT (RILPIVIRINE HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202022%22
- openFDA Drugs@FDA: "NDA202022 SUPPL-17 (Efficacy): submission_status AP, submission_status_date 20220329, review_priority PRIORITY; sponsor_name JANSSEN PRODS; product EDURANT (RILPIVIRINE HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202022%22

### March 15, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA219016 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20240315, review_priority PRIORITY; sponsor_name JANSSEN PRODS; product EDURANT PED (RILPIVIRINE HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219016%22

### March 15, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA202022 SUPPL-22 (Efficacy): submission_status AP, submission_status_date 20240315, review_priority PRIORITY; sponsor_name JANSSEN PRODS; product EDURANT (RILPIVIRINE HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202022%22
- openFDA Drugs@FDA: "NDA202022 SUPPL-20 (Efficacy): submission_status AP, submission_status_date 20240315, review_priority PRIORITY; sponsor_name JANSSEN PRODS; product EDURANT (RILPIVIRINE HYDROCHLORIDE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202022%22

### August 18, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Human Immunodeficiency Virus Type 1.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02494986 (A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-18 (ACTUAL); Lead Sponsor Janssen Sciences Ireland UC." https://clinicaltrials.gov/study/NCT02494986

### Aug to Nov 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Human Immunodeficiency Virus Type 1.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT02494986 (A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-18 (ACTUAL); Lead Sponsor Janssen Sciences Ireland UC." https://clinicaltrials.gov/study/NCT02494986

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/rilpivirine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Edurant Ped (rilpivirine hydrochloride) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/rilpivirine

```bibtex
@misc{secapidev_pdufa_rilpivirine_20261116,
  title        = {Edurant Ped (rilpivirine hydrochloride) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/rilpivirine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_rilpivirine_20261116","title":"Edurant Ped (rilpivirine hydrochloride) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/rilpivirine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
